Compare YieldMax NVDA Option Income Strategy ETF (NVDY) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax NVDA Option Income Strategy ETF vs Stryker Corporation — how do they compare? YieldMax NVDA Option Income Strategy ETF trades at $12.62, while Stryker Corporation trades at $314.62 (market cap $122.35B). The key difference: Stryker Corporation pays a 1% dividend while YieldMax NVDA Option Income Strategy ETF pays none, and Stryker Corporation is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| NVDY | SYK | |
|---|---|---|
Sector | Income / Options Overlay | Technology |
52-Week High | $17.96 | $403.53 |
52-Week Low | $12.03 | $282.58 |
Market Cap | — | $122.35B |
Enterprise Value | — | $134.10B |
Dividend Yield | — | 1% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
